Equillium(EQ) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 LA JOLLA, California, November 13, 2024 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of i ...